Thus, we propose a model where hemizygous deletion of DGCR8 leads to a decrease in microprocessor efficiency and to a dysregulation of miRNA expression, which ultimately contributes to the clinical phenotypes seen in individuals with 22q11DS (Figure 8). The gene discussed is DGCR8; the disease is 22q11.2 deletion syndrome.